Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Decreases By 18.2%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 5,830,000 shares, a drop of 18.2% from the January 31st total of 7,130,000 shares. Based on an average daily trading volume, of 371,600 shares, the days-to-cover ratio is currently 15.7 days.

KalVista Pharmaceuticals Stock Down 0.5 %

KALV stock traded down $0.06 during trading on Friday, hitting $11.92. 595,472 shares of the company's stock traded hands, compared to its average volume of 415,072. The stock has a fifty day moving average price of $9.31 and a two-hundred day moving average price of $10.31. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $15.50. The stock has a market capitalization of $589.06 million, a price-to-earnings ratio of -3.27 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. As a group, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The shares were acquired at an average cost of $9.23 per share, with a total value of $923,000.00. Following the purchase, the insider now directly owns 5,217,285 shares of the company's stock, valued at approximately $48,155,540.55. This trade represents a 1.95 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the transaction, the chief executive officer now directly owns 274,596 shares in the company, valued at $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 18,250 shares worth $179,160. Company insiders own 10.50% of the company's stock.

Remove Ads

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $44,000. Tower Research Capital LLC TRC boosted its holdings in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares in the last quarter. Martin Worley Group bought a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 price target on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a "buy" rating and a $22.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).